Krystal Biotech (NASDAQ:KRYS) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $221.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Stifel Nicolaus upped their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Citigroup increased their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital reiterated a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a research report on Thursday, December 12th. Finally, William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Stock Up 2.5 %

NASDAQ:KRYS opened at $164.83 on Wednesday. The stock has a market cap of $4.74 billion, a P/E ratio of 93.12 and a beta of 0.80. The business’s 50-day moving average price is $180.18 and its two-hundred day moving average price is $185.00. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period last year, the firm posted ($0.67) earnings per share. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. On average, equities research analysts expect that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors have recently modified their holdings of the company. Summit Trail Advisors LLC bought a new position in Krystal Biotech during the 3rd quarter valued at approximately $1,893,000. Swiss National Bank increased its stake in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after buying an additional 2,900 shares during the period. Sei Investments Co. raised its holdings in shares of Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after acquiring an additional 6,363 shares in the last quarter. Shaker Investments LLC OH purchased a new stake in Krystal Biotech in the third quarter worth $532,000. Finally, Citigroup Inc. boosted its holdings in Krystal Biotech by 65.4% in the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).